Report cover image

Looking Ahead to 2024 - the Future of Pharma?

Publisher GlobalData
Published May 02, 2024
Length 54 Pages
SKU # GBDT18867382

Description

Looking Ahead to 2024 - the Future of Pharma​


Summary

This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.

Scope

This 54-page report gives important, expert insight you won’t find in any other source. 25 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for -
  • Investors that want to understand future trends impacting the biopharmaceutical industry as well as identifying companies to invest in
  • Companies that are interested in entering the biopharmaceutical space and where best to focus on
  • Large pharma companies with investment groups or BD teams looking to see which companies are predicted to lead the industry in the near and far future
  • Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
  • Year Ahead Opportunities - looking ahead in 2024 using sales and regulatory analyses to identify events and trends that may be opportunities.
  • Year Ahead Threats -looking ahead in 2024 using sales forecasts and clinical analyses to identify events and trends that may pose a threat.
  • Future Opportunities - looking ahead to 5 years into the future, using sales forecasts and analyses to identify the opportunities in 2029 that can be exploited.
  • Clinical Trials - using clinical analyses to identify key areas within clinical trials that have begun or are planned for 2024.

Table of Contents

54 Pages
1 Year Ahead Opportunities
1.1 Top 10 Companies by Pharmaceutical Sales 2024 versus 2023
1.2 Top 10 Key Therapy Areas 2024 versus 2023
1.3 Top 10 Drugs 2024 Versus 2023
1.4 2024 Drug Launches
1.5 2024 PDUFA dates
1.6 Top 10 Targets in the Pipeline
2 Year Ahead Threats
2.1 Drug Patent Expirations
2.2 Post-Marketing Obligations
3 Future Opportunities
3.1 Risk-Adjusted Net Present Value
3.2 Sales Five Years from Now
4 Clinical Trials
4.1 Clinical Trials in 2024
4.2 Decentralized vs Centralized Clinical Trials
5 Key Findings
Appendix
6.1 Abbreviations
List of Tables
Table 1: Blockbuster drug launches in 2024
Table 2: Top 10 small molecules by sales with expected patent expiries 2024
Table 3: Top 10 Biologics by Sales with Expected Patent Expiries (2023-2025)
List of Figures
Top 10 Companies by Pharmaceutical Sales, 2024 vs. 2023
Top 10 Key Therapy Areas, 2024 vs. 2023
Top 10 Key Therapy Areas, 2024 vs. 2023
Top 10 Drugs, 2024 vs. 2023
Top 10 Biologic Drugs, 2024 vs. 2023
2024 PDUFA Dates
Top 10 companies with the most drugs in late-stage development
Top 10 biologic targets in development
Top 10 small molecule targets in development
Genomics identified as the top emerging pharmaceutical industry trend for 2024
Industry’s Growth During the Next 12 Months - Opinion Survey
Top 10 small molecules by sales with expected patent expiries 2024
Top 10 Biologics by Sales with Expected Patent Expiries (2023-2025)
PMOs by company, 2024
PMOs by drug, 2024
Top 10 drugs by 2024 by NPV
Top 10 companies by 2029 pharmaceutical sales
Percentage sales change 2024-29 for top 10 sales companies
Top 10 companies by 2029 biologic sales
Percentage sales change 2024-29 for top 10 companies by 2029 biologic sales
Small molecule versus biologic sales forecasts
mRNA versus genome editing sales forecasts
Clinical trials starting in 2024 by sponsor
Clinical trial completions by sponsor 2024
Clinical trials by entity type, 2024
Decentralized versus centralized clinical trials starting in 2024

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us